Who Owns Genmab Company?

Who owns Genmab today?

Genmab’s shareholder mix shifted from founder and strategic holders to large global institutions after its 2019 NASDAQ IPO, which raised about 582 million USD. By early 2025, institutional investors and Danish foundations dominate ownership, guiding reinvestment of royalties from drugs like Darzalex.

Institutionalization of Genmab’s cap table reflects confidence in steady royalty streams and its 2030 growth plan; major asset managers and local foundations are key decision-makers. See Genmab Porter's Five Forces Analysis.

Founders and Early Ownership of Genmab centered on a Copenhagen-led scientific team with strong backing from transatlantic partners and Danish institutional investors.

Founders

Genmab was founded in 1999 by Jan van de Winkel and Florian Schönharting with a focus on therapeutic human antibodies.

Medarex stake

Medarex provided transgenic mouse technology and held about 45% equity at inception, making it the dominant early owner.

BankInvest role

BankInvest, anchored by Schönharting, supplied early funding and institutional support from Copenhagen.

Management ownership

The founding management team held the remaining equity alongside a few Danish institutional investors, maintaining strategic control locally.

IPO and liquidity

Genmab’s 2000 IPO on the Copenhagen Stock Exchange established public Genmab stock ownership and provided an early valuation point for initial backers.

Ownership character

Early agreements emphasized transparency and scientific independence; there were no major public disputes during this phase.

Early ownership set the stage for Genmab’s corporate structure: Medarex as a major parent-technology provider, Copenhagen-based founders leading strategy, and institutional investors providing capital and governance oversight.

Key early ownership facts

Founders, strategic partner stakes, and early public listing shaped Genmab ownership and transparency.

• Medarex initially owned roughly 45% of Genmab in exchange for technology rights.
• Founders Jan van de Winkel and Florian Schönharting anchored leadership and investor relations.
• BankInvest was a principal early institutional investor supporting Copenhagen operations.
• Genmab completed its IPO in 2000 on the Copenhagen Stock Exchange, establishing public Genmab stock ownership.

See further historical corporate and ownership context in this analysis: Marketing Strategy of Genmab

The ownership of Genmab has shifted through key events: the 2000 Copenhagen IPO and the 2019 US IPO, which triggered a transfer of shares from European retail and small-cap funds to large US institutional investors; by mid-2025 institutional holders dominate the register, reshaping Genmab stock ownership and corporate structure.

Institutional investors collectively own over 85% of Genmab shares by mid-2025, reflecting a mature, large-cap biotech ownership profile where retail and founder stakes have been diluted; regulatory filings and periodic shareholder reports confirm this concentration, and question 'Does Genmab have a controlling owner' is answered by dispersed institutional ownership rather than a single controlling parent.

Major ownership implications

Large US asset managers and Nordic strategic investors jointly shape Genmab corporate strategy and capital allocation.

• Institutional ownership exceeds 85%, concentrating voting power
• Top holders: The Capital Group (~10%), BlackRock (8–9%), Novo Holdings (5–7%)
• Insiders and founders hold under 1%, typical for large-cap biotech
• See governance and cultural context in Mission, Vision & Core Values of Genmab

Genmab’s Board of Directors is chaired by Deirdre P. Connelly and includes CEO Jan van de Winkel, reflecting a governance model that ties voting power directly to economic ownership across its institutional shareholder base.

Genmab follows a one-share-one-vote policy with no dual-class shares or golden share; the top five institutional investors collectively control nearly 40% of voting power, reinforcing the need for transparency and performance-led governance.

Board balance and voting leverage

Institutional investors dominate Genmab ownership, pushing the board toward ESG-aligned practices and clear pipeline funding strategies.

• Genmab ownership aligns voting with economic stakes under one-share-one-vote
• Top five institutional shareholders hold nearly 40% of votes collectively
• Board chaired by Deirdre P. Connelly to avoid concentration of control
• Darzalex royalty strategy used to fund internal pipeline, limiting proxy conflict

For more context on strategy and shareholder alignment see Growth Strategy of Genmab

Recent ownership trends at Genmab show rising concentration after large 2024 share buybacks and a shift toward US-based healthcare specialist funds, reflecting the company’s transition to cash-flow-positive operations and reduced need for dilutive equity.

Genmab ownership now features larger institutional stakes and fewer retail holders; public statements in 2025 emphasize commitment to the Genmab 2030 strategy and developing next-generation medicines such as Epkinly and Tivdak while maintaining a listed structure and preparing leadership succession.

Buybacks and capital allocation

Buybacks in 2024 totaled several billion DKK, signaling a move to return capital rather than pursue dilutive financing amid positive cash flow.

Investor mix evolution

US healthcare specialist funds now represent a growing share of Genmab shareholders, increasing sector-focused engagement and influencing stock ownership dynamics.

Governance and leadership changes

Board and executive adjustments in 2025 aim to prepare for succession as founding members transition from active management roles.

Market positioning

Management reiterates no plans for privatization; Genmab remains a publicly traded company focused on advancing its oncology pipeline and sustaining shareholder value; see Revenue Streams & Business Model of Genmab for more.